The Basics: What Are 503A and 503B?
Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) were enacted by the Drug Quality and Security Act (DQSA) of 2013 following the 2012 meningitis outbreak linked to a non-patient-specific compounding facility. The law created two distinct regulatory pathways for compounding pharmacies, with fundamentally different rules for each.
503A — Traditional Compounding Pharmacy
- Compounds for individual patients based on valid prescriptions
- Primarily regulated by state boards of pharmacy
- Subject to state law and USP <797> standards
- Not subject to FDA cGMP inspection (generally)
- Must source bulk drug substances from FDA-evaluated lists
- Cannot distribute beyond incidental interstate amounts
503B — Outsourcing Facility
- Compounds large batches without patient-specific prescriptions
- Voluntarily registered with FDA
- Subject to FDA cGMP inspection
- Must use bulk drug substances from FDA 503B list
- Can distribute interstate to health systems & clinics
- Exempt from prescription requirement for most products
Peptide API Sourcing: What Each Designation Requires
For peptide API specifically, the sourcing requirements differ in important ways between 503A and 503B facilities:
503A Bulk Drug Substance Sourcing
Under 503A, a pharmacy may compound using bulk drug substances that: (1) are components of an FDA-approved drug; (2) appear on a list of bulk drug substances developed by FDA through notice and comment rulemaking; or (3) appear on the FDA's interim list of bulk drug substances that are not components of FDA-approved drugs but are subject to a clinical evaluation application. For peptides like semaglutide, BPC-157, and others, this creates a complex regulatory picture that varies by specific peptide and current FDA enforcement priorities.
Regardless of which peptide a 503A pharmacy is compounding, the bulk drug substance must be sourced from a manufacturer that: holds a valid FDA registration, operates under conditions consistent with cGMP, and can provide documentation (CoA, endotoxin data, supplier letters) that supports the pharmacy's compliance with USP <797> and applicable state board regulations.
503B Bulk Drug Substance Sourcing
503B outsourcing facilities have stricter requirements: they must source only from the FDA's 503B bulk drug substance list, only from facilities with current FDA Drug Master Files or FDA registration, and must have their own quality agreements and audit programs with suppliers. 503B facilities operate under full FDA cGMP oversight and are subject to FDA inspection — making documentation gaps far more consequential.
Practical Implications for Peptide Suppliers
What does this mean when you're evaluating a wholesale peptide API supplier? Regardless of whether you operate as a 503A or 503B facility, you need a supplier who:
- Manufactures in a US facility with a current FDA registration
- Provides lot-specific CoA with HPLC, MS, endotoxin, and residual solvent data
- Sources raw API from manufacturers with established FDA regulatory standing
- Provides supplier letters suitable for submission to your state board or FDA
- Has not had 483 observations or warning letters for your specific products
Frequently Asked Questions
What is the difference between a 503A and 503B pharmacy?
503A pharmacies compound for individual patients with prescriptions, regulated by state boards. 503B outsourcing facilities compound large batches without patient-specific prescriptions and are FDA-regulated under cGMP.
Can a 503A pharmacy buy peptide API from any supplier?
No. 503A pharmacies must source bulk drug substances from manufacturers with appropriate FDA regulatory standing and provide documentation supporting USP <797> and state board requirements.
Do 503B outsourcing facilities have stricter requirements than 503A pharmacies?
Yes. 503B facilities are subject to FDA inspection and cGMP, must source from the FDA 503B bulk drug substance list, and have more rigorous supplier qualification requirements.